Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT05560139 |
| Other study ID # |
TCDCS in MS |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
December 1, 2022 |
| Est. completion date |
September 1, 2023 |
Study information
| Verified date |
September 2022 |
| Source |
Assiut University |
| Contact |
Entsar karem, resident |
| Phone |
0201030698902 |
| Email |
entsarkarem07[@]gmail.com |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
This work is aimed to assess the long term effect of TDCS in fatigue management among MS
patients
Description:
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous
system that is considered one of the most frequent causes of disability in the young adult.
Fatigue in MS may affect up to 80 % of the people with MS. It tends to persist over time once
it appears. However, despite high frequency, fatigue remains poorly understood. Fatigue in MS
is neither consistently linked to disease severity nor disease duration, although it is found
to be worse in individuals with the secondary progressive subtype.
Fatigue is distinct from sleepiness, and fails to improve with adequate sleep. Multiple
factors are thought to contribute to fatigue[7 , 8] with no specific biomarker or etiology
yet confirmed.
A wide variety of therapies have been tested to reduce fatigue in MS, but unfortunately, none
have been consistently effective. Transcranial direct current stimulation (tDCS) is a
relatively recent therapeutic development that utilizes low-amplitude direct currents to
induce changes in cortical excitability. Although various non-invasive neuromodulation
technologies are available , tDCS has unique advantages compared to other stimulation methods
such as its ease of use, lower cost, and greater safety and tolerability.
Small preliminary studies have observed that tDCS may be a promising treatment for MS
fatigue, using sham-controlled crossover designs, with five tDCS sessions, using either a
motor, sensory, or dorsolateral prefrontal cortex (DLPFC). Recently Chalah et al.[12] study
demonstrated that DLPFC (left anodal) when compared the posterior parietal cortex led to the
most fatigue specific improvements.
Thus, tDCS can reduce fatigue burden for people with MS, it may be possible to implement a
tDCS therapy for symptomatic management of fatigue.
